Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Aeolus Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
AOLS's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6 * Ranked among companies with meaningful Equity-to-Asset only.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aeolus Pharmaceuticals Equity-to-Asset Related Terms
Aeolus Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aeolus Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AOLS vs RDGL, PCYN, YBAO: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aeolus Pharmaceuticals Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aeolus Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aeolus Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Sep. 2016 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aeolus Pharmaceuticals (AOLS) has a Equity-to-Asset of 0.26 as of Jun. 2017. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Equity-to-Asset too high?
Aeolus Pharmaceuticals' current Equity-to-Asset is 0.26. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Aeolus Pharmaceuticals' value of 0.26 is 56.7% below this industry median.
How does Aeolus Pharmaceuticals' Equity-to-Asset compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Equity-to-Asset of 0.26 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.60. Aeolus Pharmaceuticals' value of 0.26 is 56.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aeolus Pharmaceuticals's current Equity-to-Asset of 0.26 is 56.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aeolus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aeolus Pharmaceuticals's current Equity-to-Asset is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Equity-to-Asset of 0.26. The current Equity-to-Asset is 0.26 and 56.7% below the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Equity-to-Asset is 0.26 as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AOLS has been successfully added to your 
